Naveed Syed: Sometimes Rejection Strengthens Research
Naveed Syed, Hematology Specialist at Sheikh Shakhbout Medical City, shared a post on LinkedIn:
“Sometimes the best thing that can happen to your research is a rejection by experts in your own field.
If it isn’t being rejected, you’re probably not aiming high enough.
Reviewer feedback—though demanding—helps elevate the quality of any manuscript. While we work on these improvements, preprint platforms ensure the work remains visible and accessible.
This is our second article from the team: the first was a single-centre analysis, and now we present a first multi-centre, 14-year UAE stem cell transplant study, described in granular detail (disease level). We have tried to be as transparent as possible in reporting the data.
Until the revised version is ready and publsihed, the preprint is available for those interested.”
Read the full article here.
Article: Long-term outcomes and GVHD in patients receiving hematopoietic cell transplants abroad: A 14-year UAE multi-center cohort
Authors: Naveed Syed, Mohamed Abuhaleeqa, Fatema Mohammed Al Kaabi, Naser Alzein, Zainul Aabideen, Aydah M. Al-Awadhi, Arif Alam, Azmat Ali Khan, Imrana Afrooz, Farooq Ahmed Mir, Riad Alhasan, Moussab Damlaj, Osama Taher Anaam, Manar Hassan Mohamed, Gehad ElGhazali, Kayane Mheidly, Shahrukh Hashmi

Stay informed with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
